[
    [
        {
            "time": "",
            "original_text": "大摩：医药股面对政策逆风 首选信达生物(01801.HK)等",
            "features": {
                "keywords": [
                    "医药股",
                    "政策逆风",
                    "信达生物"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大摩：医药股面对政策逆风 首选信达生物(01801.HK)等",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]